Get the Stockscreener App
13.15
1.54%
0.20
After Hours:
13.15
Y Mabs Therapeutics Inc stock is traded at $13.15, with a volume of 104.19K.
It is up +1.54% in the last 24 hours and down -8.11% over the past month.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
See More
Previous Close:
$12.95
Open:
$12.86
24h Volume:
104.19K
Relative Volume:
0.37
Market Cap:
$584.31M
Revenue:
$84.82M
Net Income/Loss:
$-21.43M
P/E Ratio:
-14.78
EPS:
-0.89
Net Cash Flow:
$-27.23M
1W Performance:
+0.69%
1M Performance:
-8.11%
6M Performance:
-19.13%
1Y Performance:
+141.28%
1-Day Range:
$12.84
$13.44
1-Week Range:
$12.70
$13.44
52-Week Range:
$4.69
$20.90
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
Name
Y Mabs Therapeutics Inc
Sector
Industry
Phone
212-847-9841
Address
230 PARK AVENUE, NEW YORK, NY
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-10-23 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-27-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-05-23 | Downgrade | Cowen | Outperform → Market Perform |
| Dec-02-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-31-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-31-22 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-03-22 | Resumed | Guggenheim | Buy |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-16-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-07-21 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-23-21 | Resumed | Cowen | Outperform |
| Mar-22-21 | Resumed | JP Morgan | Overweight |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| May-05-20 | Initiated | Barclays | Overweight |
| May-01-20 | Initiated | Janney | Buy |
| Apr-29-20 | Initiated | Morgan Stanley | Equal-Weight |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Initiated | Wedbush | Outperform |
| Apr-01-19 | Initiated | H.C. Wainwright | Buy |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Oct-16-18 | Initiated | BofA/Merrill | Buy |
View All
Y Mabs Therapeutics Inc Stock (YMAB) Latest News
Y-mAbs Therapeutics' SWOT analysis: innovative cancer therapy stock faces pivotal year - Investing.com India
While shareholders of Y-mAbs Therapeutics (NASDAQ:YMAB) are in the black over 1 year, those who bought a week ago aren't so fortunate - Yahoo Finance
Jamf (NASDAQ:JAMF) Shares Gap Down to $18.70 - MarketBeat
Needham maintains Buy rating on Jamf shares with no price target change - Investing.com India
Jamf (NASDAQ:JAMF) Earns “Market Outperform” Rating from JMP Securities - Defense World
Jamf's (JAMF) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
272 Capital LP Acquires 44,486 Shares of Jamf Holding Corp. (NASDAQ:JAMF) - MarketBeat
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 4.7% - MarketBeat
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 4.7% - Defense World
Stock Surge: Y-Mabs Therapeutics Inc (YMAB) Closes at 13.73, Marking a -1.93 Increase/Decrease - The Dwinnex
Examining the Potential Price Growth of Jamf Holding Corp (JAMF) - Knox Daily
How To Trade (YMAB) - Stock Traders Daily
Nothing is Better Than Y-Mabs Therapeutics Inc (YMAB) stock at the moment - SETE News
Massachusetts Financial Services Co. MA Increases Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Founder Thomas Gad Sold A Bunch Of Shares In Y-mAbs Therapeutics - Simply Wall St
FDA Approves Amivantamab (Rybrevant) Plus Chemo for EGFR-Mutated Advanced NSCLC - OBR Oncology
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Holdings Lifted by Bank of New York Mellon Corp - Defense World
Amivantamab Plus Chemo Approved by FDA in EGFR-Mutated NSCLC - Cancer Network
FDA Approves Amivantamab-Chemo Combo for Advanced NSCLC - www.oncnursingnews.com/
Edgestream Partners L.P. Invests $2.23 Million in Jamf Holding Corp. (NASDAQ:JAMF) - Defense World
Thomas Gad Sells 30,000 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Stock - Defense World
Thomas Gad Sells 65,000 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Stock - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 6.9% - Defense World
Jamf's (JAMF) Market Outperform Rating Reaffirmed at JMP Securities - MarketBeat
Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 8.1% - MarketBeat
Y-mAbs Therapeutics signs new headquarters lease - Investing.com
Y-mAbs Therapeutics signs new headquarters lease - Investing.com India
Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Down 6.9% - MarketBeat
Acadian Asset Management LLC Sells 279,139 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - MarketBeat
Acadian Asset Management LLC Sells 279,139 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
When the Price of (YMAB) Talks, People Listen - Stock Traders Daily
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Held Back By Insufficient Growth Even After Shares Climb 33% - Simply Wall St
Y-mAbs Therapeutics’ (YMAB) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Wedbush Reaffirms Outperform Rating for Y-mAbs Therapeutics (NASDAQ:YMAB) - MarketBeat
Y-mAbs Therapeutics (NASDAQ:YMAB) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Given "Overweight" Rating at Cantor Fitzgerald - MarketBeat
Navigating 8 Analyst Ratings For Y-mAbs Therapeutics - Benzinga
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $21.14 Average Price Target from Brokerages - MarketBeat
Y-mAbs reports progress in neuroblastoma treatments - Investing.com India
Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research - ForexTV.com
Y-mAbs reports progress in neuroblastoma treatments By Investing.com - Investing.com Canada
Brokerage maintains stock target on Y-mAbs, cites positive study data - Investing.com
Y-mAbs reports progress in neuroblastoma treatments - Investing.com
Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research - StockTitan
YMAB Shares Experience Surge in Value - Knox Daily
Institutional investors may overlook Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) recent US$57m market cap drop as long-term gains remain positive - Simply Wall St
Y-mAbs to Participate in Upcoming Investor Conferences in September - Yahoo Finance UK
Y-mAbs to Participate in Upcoming Investor Conferences in September - StockTitan
Is Y-Mabs Therapeutics Inc (YMAB) worth investing in despite its overvalued state? - US Post News
The growth track for Y-Mabs Therapeutics Inc (YMAB) has changed recently - SETE News
Y Mabs Therapeutics Inc Stock (YMAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):